Ultragenyx Pharmaceutical (RARE) Capital Expenditures Growth (3y) (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.71 Bn | 2.30 Bn | 106.00 Mn | -65.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.82% |
| Dec 31, 2025 | -78.60% |
| Sep 30, 2025 | 26.62% |
| Jun 30, 2025 | -55.18% |
| Mar 31, 2025 | -68.56% |
| Dec 31, 2024 | 30.34% |
| Sep 30, 2024 | -33.90% |
| Jun 30, 2024 | -26.39% |
| Mar 31, 2024 | -57.28% |
| Dec 31, 2023 | -34.44% |
| Sep 30, 2023 | -0.76% |
| Jun 30, 2023 | 50.57% |
| Mar 31, 2023 | 21.10% |
| Dec 31, 2022 | 224.82% |
| Sep 30, 2022 | -118.83% |
| Jun 30, 2022 | 80.71% |
| Mar 31, 2022 | 119.12% |
| Dec 31, 2021 | -182.27% |
| Sep 30, 2021 | 171.09% |
| Jun 30, 2021 | 132.69% |